Citations (116)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Piyush Baindara, Sonali Agrawal & O. L. Franco. (2022) Host-directed therapies for malaria and tuberculosis: common infection strategies and repurposed drugs. Expert Review of Anti-infective Therapy 20:6, pages 849-869.
Read now
Read now
Fanhua Wei, Chengjiang Gao & Yujiong Wang. (2022) The role of influenza A virus-induced hypercytokinemia. Critical Reviews in Microbiology 48:2, pages 240-256.
Read now
Read now
Hayrunnisa Nadaroglu. (2020) Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm. Drug Metabolism Reviews 52:4, pages 531-539.
Read now
Read now
Jungan Zhang, Peipei Li, Hongyun Zeng, Yu Huang & Wei Hong. (2020) Highly efficient and green synthesis of 2,4-diphenyl substituted thiazoles. Synthetic Communications 50:5, pages 735-741.
Read now
Read now
Erwin van den Enden. (2009) Pharmacotherapy of helminth infection. Expert Opinion on Pharmacotherapy 10:3, pages 435-451.
Read now
Read now
Joseph Guiles, Ian Critchley & Xicheng Sun. (2008) New agents for Clostridium difficile-associated disease. Expert Opinion on Investigational Drugs 17:11, pages 1671-1683.
Read now
Read now
Roberto Cañete, Angel A. Escobedo, Maria Elena González, Pedro Almirall & Nereyda Cantelar. (2006) A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Current Medical Research and Opinion 22:11, pages 2131-2136.
Read now
Read now
Simone M Cacciò & Edoardo Pozio. (2006) Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert Review of Anti-infective Therapy 4:3, pages 429-443.
Read now
Read now
Andrew Hemphill, Joachim Mueller & Marco Esposito. (2006) Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opinion on Pharmacotherapy 7:7, pages 953-964.
Read now
Read now
Elizabeth S Didier, Joseph A Maddry, Paul J Brindley, Mary E Stovall & Peter J Didier. (2005) Therapeutic strategies for human microsporidia infections. Expert Review of Anti-infective Therapy 3:3, pages 419-434.
Read now
Read now
Articles from other publishers (106)
Sidra Bashir, Kanwal Shabbir, Fakhar ud Din, Saif Ullah Khan, Zakir Ali, Barkat Ali Khan, Dong Wuk Kim & Gul Majid Khan. (2023) Nitazoxanide and quercetin co-loaded nanotransfersomal gel for topical treatment of cutaneous leishmaniasis with macrophage targeting and enhanced anti-leishmanial effect. Heliyon 9:11, pages e21939.
Crossref
Crossref
Yanbai Li, Shanshan Huo, Zhe Yin, Zuguang Tian, Fang Huang, Peng Liu, Yue Liu & Fei Yu. (2023) The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. mBio 14:5.
Crossref
Crossref
Xiaoyi Liu, Jing Wang, Jun Liu, Xuming Li, Yuanlin Guan, Suyun Qian & Xinlei Jia. (2023) Cryptosporidiosis diagnosed using metagenomic next-generation sequencing in a healthy child admitted to pediatric intensive care unit: a case report. Frontiers in Cellular and Infection Microbiology 13.
Crossref
Crossref
Niharika Amireddy, Vandana Dulam, Shweta Kaul, Rajeswari Pakkiri & Shasi V. Kalivendi. (2023) The mitochondrial uncoupling effects of nitazoxanide enhances cellular autophagy and promotes the clearance of α-synuclein: Potential role of AMPK-JNK pathway. Cellular Signalling 109, pages 110769.
Crossref
Crossref
Andrea Angeli, Victor Kartsev, Anthi Petrou, Boris Lichitsky, Andrey Komogortsev, Athina Geronikaki & Claudiu T. Supuran. (2023) Substituted furan sulfonamides as carbonic anhydrase inhibitors: Synthesis, biological and in silico studies. Bioorganic Chemistry 138, pages 106621.
Crossref
Crossref
Abeer A. Sharfalddin, Inas M. Al-Younis, Abdul-Hamid Emwas & Mariusz Jaremko. (2023) Investigating the Biological Potency of Nitazoxanide-Based Cu(II), Ni(II) and Zn(II) Complexes Synthesis, Characterization and Anti-COVID-19, Antioxidant, Antibacterial and Anticancer Activities. Molecules 28:16, pages 6126.
Crossref
Crossref
Víctor Martínez-Rosas, Beatriz Hernández-Ochoa, Laura Morales-Luna, Daniel Ortega-Cuellar, Abigail González-Valdez, Roberto Arreguin-Espinosa, Yadira Rufino-González, Ernesto Calderón-Jaimes, Rosa Angélica Castillo-Rodríguez, Carlos Wong-Baeza, Isabel Baeza-Ramírez, Verónica Pérez de la Cruz, Abraham Vidal-Limón & Saúl Gómez-Manzo. (2023) Nitazoxanide Inhibits the Bifunctional Enzyme GlG6PD::6PGL of Giardia lamblia: Biochemical and In Silico Characterization of a New Druggable Target. International Journal of Molecular Sciences 24:14, pages 11516.
Crossref
Crossref
Elisa Souza Vaz, Sandra Valeria Vassiliades, Jeanine Giarolla, Michelle Carneiro Polli & Roberto Parise-Filho. (2023) Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. European Journal of Clinical Pharmacology 79:6, pages 723-751.
Crossref
Crossref
Qingqing Huang, Mingcheng Liu, Duo Zhang, Bing-Biao Lin, Xing Fu, Zhiqian Zhang, Baotong Zhang & Jin-Tang Dong. (2023) Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer. BMC Medicine 21:1.
Crossref
Crossref
Mahmoud Saleh, Yaser A. Mostafa, Jyothi Kumari, Momen M. Thabet, Dharmarajan Sriram, Mahmoud Kandeel & Hajjaj H. M. Abdu-Allah. (2023) New nitazoxanide derivatives: design, synthesis, biological evaluation, and molecular docking studies as antibacterial and antimycobacterial agents. RSC Medicinal Chemistry.
Crossref
Crossref
Yanxun Li, Congcong Li, Xiaoqiang Gao & Hekun Lv. (2023) Nitazoxanide in aqueous co-solvent solutions of isopropanol/DMF/NMP: Solubility, solvation thermodynamics and intermolecular interactions. The Journal of Chemical Thermodynamics 176, pages 106928.
Crossref
Crossref
Bruna Sabatke, Pedro Felipe P. Chaves, Lucimara M. C. Cordeiro & Marcel I. Ramirez. (2022) Synergistic Effect of Polysaccharides from Chamomile Tea with Nitazoxanide Increases Treatment Efficacy against Giardia intestinalis. Life 12:12, pages 2091.
Crossref
Crossref
Abeer A. Sharfalddin, Enas Inas Muta'eb Alyounis, Abdul-Hamid Emwas & Mariusz Jaremko. (2022) Biological efficacy of novel metal complexes of Nitazoxanide: Synthesis, characterization, anti-COVID-19, antioxidant, antibacterial and anticancer activity studies. Journal of Molecular Liquids 368, pages 120808.
Crossref
Crossref
Upala Dasmahapatra & Kaushik Chanda. (2022) Synthetic approaches to potent heterocyclic inhibitors of tuberculosis: A decade review. Frontiers in Pharmacology 13.
Crossref
Crossref
Victor Kartsev, Athina Geronikaki, Alexander Zubenko, Anthi Petrou, Marija Ivanov, Jasmina Glamočlija, Marina Sokovic, Lyudmila Divaeva, Anatolii Morkovnik & Alexander Klimenko. (2022) Synthesis and Antimicrobial Activity of New Heteroaryl(aryl) Thiazole Derivatives Molecular Docking Studies. Antibiotics 11:10, pages 1337.
Crossref
Crossref
Dau Xuan Duc & Nguyen Thi Chung. (2022) Recent Development in the Synthesis of Thiazoles. Current Organic Synthesis 19:6, pages 702-730.
Crossref
Crossref
Behnam Mohammadi-Ghalehbin, Jafar Abbasi Shiran, Nastaran Gholizadeh & Nima Razzaghi-Asl. (2022) Synthesis, antileishmanial activity and molecular modeling of new 1-aryl/alkyl-3-benzoyl/cyclopropanoyl thiourea derivatives. Molecular Diversity.
Crossref
Crossref
Mahsa Ebrahimi & Omid Akhavan. (2022) Nanomaterials for Photocatalytic Degradations of Analgesic, Mucolytic and Anti-Biotic/Viral/Inflammatory Drugs Widely Used in Controlling SARS-CoV-2. Catalysts 12:6, pages 667.
Crossref
Crossref
Zhonglei Wang & Liyan Yang. (2021) Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges. Journal of Medical Virology 94:4, pages 1373-1390.
Crossref
Crossref
Helga Rübsamen‐Schaeff & Helmut BuschmannOliver Planz. 2022. New Drug Development for Known and Emerging Viruses. New Drug Development for Known and Emerging Viruses
59
96
.
Xi He, Wenjun Hu, Fanhua Meng & Xingzhou Li. (2022) Design, Synthesis, and Pharmacokinetic Evaluation of O-Carbamoyl Tizoxanide Prodrugs. Medicinal Chemistry 18:1, pages 140-150.
Crossref
Crossref
Chang-hong Li, Zi-rui Lü, Zhen-da Zhao, Xin-yu Wang, Hui-jie Leng, Yan Niu & Mo-pei Wang. (2021) Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis. Frontiers in Pharmacology 12.
Crossref
Crossref
Noha M. Abd El-Fadeal, Mohamed S. Nafie, Mohammed K. El-kherbetawy, Amr El-mistekawy, Hala M. F. Mohammad, Alaaeldeen M. Elbahaie, Abdullah A. Hashish, Suliman Y. Alomar, Sheka Yagub Aloyouni, Mohamed El-dosoky, Khaled M. Morsy & Sawsan A. Zaitone. (2021) Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt/β-Catenin Signaling Inhibition. International Journal of Molecular Sciences 22:10, pages 5213.
Crossref
Crossref
Zirui Lü, Xiaona Li, Kebin Li, Cong Wang, Tingting Du, Wei Huang, Ming Ji, Changhong Li, Fengrong Xu, Ping Xu & Yan Niu. (2021) Structure–Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors. ACS Medicinal Chemistry Letters 12:5, pages 696-703.
Crossref
Crossref
Ashkan Bagheri, Seyed Mohammad Iman Moezzi, Pouria Mosaddeghi, Sadra Nadimi Parashkouhi, Seyed Mostafa Fazel Hoseini, Fatemeh Badakhshan & Manica Negahdaripour. (2021) Interferon-inducer antivirals: Potential candidates to combat COVID-19. International Immunopharmacology 91, pages 107245.
Crossref
Crossref
Hang Liang, Li Zhang, Lina Wang, Man Gao, Xiangfeng Meng, Mengyao Li, Junhui Liu, Wei Li & Fanzheng Meng. (2021) Repositioning Drugs on Human Influenza A Viruses Based on a Novel Nuclear Norm Minimization Method. Frontiers in Physiology 11.
Crossref
Crossref
Amit S. Lokhande & Padma V. Devarajan. (2021) A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19. European Journal of Pharmacology 891, pages 173748.
Crossref
Crossref
Anton Firth & Praveen Prathapan. (2021) Broad-spectrum therapeutics: A new antimicrobial class. Current Research in Pharmacology and Drug Discovery 2, pages 100011.
Crossref
Crossref
Tommaso Felicetti, Giuseppe Manfroni, Violetta Cecchetti & Rolando Cannalire. (2020) Broad‐Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View. ChemMedChem 15:24, pages 2391-2419.
Crossref
Crossref
Mohammad Rashidul Hashan, Khaled Mosaad Elhusseiny, Le Huu-Hoai, Thuan Minh Tieu, Soon Khai Low, Le Huu Nhat Minh, Thai Le Ba Nghia, Le Quang Loc, Mai Nhu Y, Peter Samuel Eid, Mohammed Abed, Salma Said Elkolaly, Gehad Mohamed Tawfik & Nguyen Tien Huy. (2020) Effect of nitazoxanide on diarrhea: A systematic review and network meta-analysis of randomized controlled trials. Acta Tropica 210, pages 105603.
Crossref
Crossref
Malak Kaddoura, Malak AlIbrahim, Ghina Hijazi, Nadia Soudani, Amani Audi, Habib Alkalamouni, Salame Haddad, Ali Eid & Hassan Zaraket. (2020) COVID-19 Therapeutic Options Under Investigation. Frontiers in Pharmacology 11.
Crossref
Crossref
Haojian Zhang, Yuli Shi & Haoji Wang. (2020)
Solubility Determination of Nitazoxanide in Twelve Organic Solvents from
T
= 273.15 to 313.15 K
. Journal of Chemical & Engineering Data 65:7, pages 3645-3651.
Crossref
Crossref
Mohamed A. Tantawy, Nagla A. El-Sherbeeny, Nawal Helmi, Reem Alazragi, Neveen Salem & Samah M. Elaidy. (2020) Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study. Molecular and Cellular Biochemistry 469:1-2, pages 143-157.
Crossref
Crossref
Marina Claire Vinaud, Daniel Real, Carolina Miguel Fraga, Nayana F Lima, Ruy De Souza Lino Junior, Darío Leonardi & Claudio J Salomon. (2020)
Nanodelivery of nitazoxanide: impact on the metabolism of
Taenia crassiceps
cysticerci intracranially inoculated in mice
. Therapeutic Delivery 11:5, pages 329-339.
Crossref
Crossref
Ananda Kumar Konreddy, Grandhe Usha Rani, Kyeong Lee & Yongseok Choi. (2019) Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics. Current Medicinal Chemistry 26:28, pages 5363-5388.
Crossref
Crossref
Paul Manka, Amos Zeller & Wing-Kin Syn. (2019) Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 79:9, pages 903-927.
Crossref
Crossref
Kent Miner, Katja Labitzke, Benxian Liu, Paul Wang, Kathryn Henckels, Kevin Gaida, Robin Elliott, Jian Jeffrey Chen, Longbin Liu, Anh Leith, Esther Trueblood, Kelly Hensley, Xing-Zhong Xia, Oliver Homann, Brian Bennett, Mike Fiorino, John Whoriskey, Gang Yu, Sabine Escobar, Min Wong, Teresa L. Born, Alison Budelsky, Mike Comeau, Dirk Smith, Jonathan Phillips, James A. Johnston, Joseph G. McGivern, Kerstin Weikl, David Powers, Karl Kunzelmann, Deanna Mohn, Andreas Hochheimer & John K. Sullivan. (2019) Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways. Frontiers in Pharmacology 10.
Crossref
Crossref
Nayana F. Lima, Guaraciara A. Picanço, Daniella de S.M.M. Alves, Luciana D. Silva, Eliana Isac, Tatiane L. Costa, Ruy de S. Lino Junior & Marina C. Vinaud. (2019) Oral nitazoxanide treatment of experimental neurocysticercosis induces gluconeogenesis in Taenia crassiceps cysticerci. Acta Tropica 190, pages 361-364.
Crossref
Crossref
Joshua Odingo, Mai A. Bailey, Megan Files, Julie V. Early, Torey Alling, Devon Dennison, Julie Bowman, Suryakanta Dalai, Naresh Kumar, Jeffrey Cramer, Thierry Masquelin, Philip A. Hipskind & Tanya Parish. (2017)
In Vitro Evaluation of Novel Nitazoxanide Derivatives against
Mycobacterium tuberculosis
. ACS Omega 2:9, pages 5873-5890.
Crossref
Crossref
Niharika Amireddy, Srinivas N. Puttapaka, Ravali L. Vinnakota, Halley G. Ravuri, Swaroop Thonda & Shasi V. Kalivendi. (2017) The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice. Journal of Biological Chemistry 292:38, pages 15731-15743.
Crossref
Crossref
Nagendran Tharmalingam, Elamparithi Jayamani, Rajmohan Rajamuthiah, Dawilmer Castillo, Beth Burgwyn Fuchs, Michael J Kelso & Eleftherios Mylonakis. (2017)
Activity of a novel protonophore against methicillin-resistant
Staphylococcus aureus
. Future Medicinal Chemistry 9:12, pages 1401-1411.
Crossref
Crossref
Zhong Li, Matthew Brecher, Yong-Qiang Deng, Jing Zhang, Srilatha Sakamuru, Binbin Liu, Ruili Huang, Cheri A Koetzner, Christina A Allen, Susan A Jones, Haiying Chen, Na-Na Zhang, Min Tian, Fengshan Gao, Qishan Lin, Nilesh Banavali, Jia Zhou, Nathan Boles, Menghang Xia, Laura D Kramer, Cheng-Feng Qin & Hongmin Li. (2017) Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Research 27:8, pages 1046-1064.
Crossref
Crossref
Paulina Koszalka, Danielle Tilmanis & Aeron C. Hurt. (2017) Influenza antivirals currently in late-phase clinical trial. Influenza and Other Respiratory Viruses 11:3, pages 240-246.
Crossref
Crossref
Anuradha Gupta, Sachin L. Tulsankar, Rabi S. Bhatta & Amit Misra. (2017) Pharmacokinetics, Metabolism, and Partial Biodistribution of “Pincer Therapeutic” Nitazoxanide in Mice following Pulmonary Delivery of Inhalable Particles. Molecular Pharmaceutics 14:4, pages 1204-1211.
Crossref
Crossref
Raseen Tariq & Sahil Khanna. (2016) Clostridium difficile infection: Updates in management. Indian Journal of Gastroenterology 36:1, pages 3-10.
Crossref
Crossref
Anuradha Gupta, Jairam Meena, Deepak Sharma, Pushpa Gupta, Umesh Dutta Gupta, Sadan Kumar, Sharad Sharma, Amulya K Panda & Amit Misra. (2016) Inhalable Particles for “Pincer Therapeutics” Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis. Molecular Pharmaceutics 13:9, pages 3247-3255.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
749
764
.
Xinxin FengWei Zhu, Lici A. Schurig-BriccioSteffen LindertCarolyn ShoenReese HitchingsJikun LiYang WangNoman BaigTianhui ZhouBoo Kyung KimDean C. CrickMichael CynamonJ. Andrew McCammonRobert B. Gennis & Eric Oldfield. (2015) Antiinfectives targeting enzymes and the proton motive force. Proceedings of the National Academy of Sciences 112:51.
Crossref
Crossref
Ekhlas H. Abdel-Hafeez, Azza K. Ahmad, Amany M. Kamal, Manal Z. M. Abdellatif & Noha H. Abdelgelil. (2015) In vivo antiprotozoan effects of garlic (Allium sativum) and ginger (Zingiber officinale) extracts on experimentally infected mice with Blastocystis spp.. Parasitology Research 114:9, pages 3439-3444.
Crossref
Crossref
Susana A. Zevallos LESCANO, Sergio Vieira dos SANTOS, Jesiel Maurício Lemos ASSIS & Pedro Paulo CHIEFFI. (2015) EFFICACY OF NITAZOXANIDE AGAINST Toxocara canis: LARVAL RECOVERY AND HUMORAL IMMUNE RESPONSE IN EXPERIMENTALLY INFECTED MICE. Revista do Instituto de Medicina Tropical de São Paulo 57:4, pages 337-341.
Crossref
Crossref
Vitaliano A. Cama & Blaine A. Mathison. (2015) Infections by Intestinal Coccidia and Giardia duodenalis. Clinics in Laboratory Medicine 35:2, pages 423-444.
Crossref
Crossref
Giuseppe Belardo, Orlando Cenciarelli, Simone La Frazia, Jean Francois Rossignol & M. Gabriella Santoro. (2015)
Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses
In Vitro
. Antimicrobial Agents and Chemotherapy 59:2, pages 1061-1069.
Crossref
Crossref
Nicola Di Santo & Jessie Ehrisman. (2014) A functional perspective of nitazoxanide as a potential anticancer drug. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 768, pages 16-21.
Crossref
Crossref
Katherine T. Andrews, Gillian Fisher & Tina S. Skinner-Adams. (2014) Drug repurposing and human parasitic protozoan diseases. International Journal for Parasitology: Drugs and Drug Resistance 4:2, pages 95-111.
Crossref
Crossref
Igor Rafael dos Santos Magalhães. (2014) Current bioanalytical methods for pharmacokinetic studies of drugs used in neglected tropical diseases. Bioanalysis 6:12, pages 1711-1723.
Crossref
Crossref
Markus Arnold, Elisabeth Lang, Paola Modicano, Rosi Bissinger, Caterina Faggio, Majed Abed & Florian Lang. (2014) Effect of Nitazoxanide on Erythrocytes. Basic & Clinical Pharmacology & Toxicology 114:5, pages 421-426.
Crossref
Crossref
Fan Zhang & Gang Wang. (2014) A review of non-nucleoside anti-hepatitis B virus agents. European Journal of Medicinal Chemistry 75, pages 267-281.
Crossref
Crossref
Simone La Frazia, Alessandra Ciucci, Francesca Arnoldi, Maurizio Coira, Patrizia Gianferretti, Mara Angelini, Giuseppe Belardo, Oscar R. Burrone, Jean-Francois Rossignol & M. Gabriella Santoro. (2013) Thiazolides, a New Class of Antiviral Agents Effective against Rotavirus Infection, Target Viral Morphogenesis, Inhibiting Viroplasm Formation. Journal of Virology 87:20, pages 11096-11106.
Crossref
Crossref
Nicola Di Santo & Jessie Ehrisman. (2013) Research Perspective: Potential Role of Nitazoxanide in Ovarian Cancer Treatment. Old Drug, New Purpose?. Cancers 5:4, pages 1163-1176.
Crossref
Crossref
Hua Fan-Minogue, Sandhya Bodapati, David Solow-Cordero, Alice Fan, Ramasamy Paulmurugan, Tarik F. Massoud, Dean W. Felsher & Sanjiv S. Gambhir. (2013) A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide. Molecular Cancer Therapeutics 12:9, pages 1896-1905.
Crossref
Crossref
Meagan A. Barry, Jill E. Weatherhead, Peter J. Hotez & Laila Woc-Colburn. (2013) Childhood Parasitic Infections Endemic to the United States. Pediatric Clinics of North America 60:2, pages 471-485.
Crossref
Crossref
Namita Jaggi. (2013) Newer Antiparasitic Agents. Journal of Patient Safety & Infection Control 1:1, pages 27-28.
Crossref
Crossref
G. Cinquetti, M.-P. Massoure & P. Rey. (2013) Traitement des parasitoses digestives (amœbose exclue). EMC - Gastro-entérologie 8:1, pages 1-10.
Crossref
Crossref
Noriyuki Nagata, Deborah Marriott, John Harkness, John T. Ellis & Damien Stark. (2012) Current treatment options for Dientamoeba fragilis infections. International Journal for Parasitology: Drugs and Drug Resistance 2, pages 204-215.
Crossref
Crossref
Anita Cohen, Pierre Verhaeghe, Maxime D. Crozet, Sébastien Hutter, Pascal Rathelot, Patrice Vanelle & Nadine Azas. (2012) Tandem synthesis and in vitro antiplasmodial evaluation of new naphtho[2,1-d]thiazole derivatives. European Journal of Medicinal Chemistry 55, pages 315-324.
Crossref
Crossref
Karen K. Y. Lam, Xingji Zheng, Roberto Forestieri, Aruna D. Balgi, Matt Nodwell, Sarah Vollett, Hilary J. Anderson, Raymond J. Andersen, Yossef Av-Gay & Michel Roberge. (2012) Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis. PLoS Pathogens 8:5, pages e1002691.
Crossref
Crossref
G. Cinquetti, M.-P. Massoure & P. Rey. (2012) Traitement des parasitoses digestives (amœbose exclue). EMC - Maladies infectieuses 9:1, pages 1-10.
Crossref
Crossref
David Brown,. 2011. Neglected Diseases and Drug Discovery. Neglected Diseases and Drug Discovery
262
289
.
Y Pouliot, A P Chiang & A J Butte. (2011) Predicting Adverse Drug Reactions Using Publicly Available PubChem BioAssay Data. Clinical Pharmacology & Therapeutics 90:1, pages 90-99.
Crossref
Crossref
Joachim Müller & Andrew Hemphill. (2011) Identification of a host cell target for the thiazolide class of broad-spectrum anti-parasitic drugs. Experimental Parasitology 128:2, pages 145-150.
Crossref
Crossref
Roberta M O'Connor, Rehaan Shaffie, Gagandeep Kang & Honorine D Ward. (2011) Cryptosporidiosis in patients with HIV/AIDS. AIDS 25:5, pages 549-560.
Crossref
Crossref
David J. Diemert. 2011. Tropical Infectious Diseases: Principles, Pathogens and Practice. Tropical Infectious Diseases: Principles, Pathogens and Practice
794
798
.
Jonathan Keshishian, Stephen G. Brantley & Patrick G. Brady. (2010) Biliary Fascioliasis Mimicking Sphincter of Oddi Dysfunction. Southern Medical Journal 103:4, pages 366-368.
Crossref
Crossref
C. Carranza-Rodríguez, F. Mateos-Rodríguez, A. Muro & J.L. Pérez Arellano. (2010) Tratamiento antiparasitario. Medicine - Programa de Formación Médica Continuada Acreditado 10:54, pages 3664-3672.
Crossref
Crossref
B. Stadelmann, S. Scholl, J. Muller & A. Hemphill. (2010) Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. Journal of Antimicrobial Chemotherapy 65:3, pages 512-519.
Crossref
Crossref
A. CLINTON WHITEJRJR. 2010. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
3547
3560
.
Martin Schlitzer, Regina Ortmann & Imke Form. (2010) Wirkstoffe gegen Wurm- und Protozoenerkrankungen und das Virustatikum Ribavirin. Medizinische Chemie einiger “Exoten”. Pharmazie in unserer Zeit 39:1, pages 18-26.
Crossref
Crossref
Simone M. Cacciò, Edoardo Pozio, Alfredo Guarino & Fabio Albano. 2009. Sequelae and Long-Term Consequences of Infectious Diseases. Sequelae and Long-Term Consequences of Infectious Diseases
245
257
.
M. J. Chan-Bacab, E. Hernandez-Nunez & G. Navarrete-Vazquez. (2009) Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana) in vitro. Journal of Antimicrobial Chemotherapy 63:6, pages 1292-1293.
Crossref
Crossref
Archana Bhaskaran & A Clinton White. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences.
Daniel M. Musher, Nancy Logan, Adam M. Bressler, David P. Johnson & Jean‐François Rossignol. (2009)
Nitazoxanide versus Vancomycin in
Clostridium difficile
Infection: A Randomized, Double‐Blind Study
. Clinical Infectious Diseases 48:4, pages e41-e46.
Crossref
Crossref
Ramakrishna U. Rao, Yuefang Huang, Kerstin Fischer, Peter U. Fischer & Gary J. Weil. (2009) Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. Experimental Parasitology 121:1, pages 38-45.
Crossref
Crossref
Theresa J. Ochoa & A. Clinton WhiteJr.Jr.. 2009. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. Feigin and Cherry's Textbook of Pediatric Infectious Diseases
2869
2880
.
. 2009. Emerging Issues and Controversies in Infectious Disease. Emerging Issues and Controversies in Infectious Disease
189
225
.
Joachim Müller, Daniel Sidler, Ueli Nachbur, Jonathan Wastling, Thomas Brunner & Andrew Hemphill. (2008)
Thiazolides inhibit growth and induce glutathione‐
S
‐transferase Pi (GSTP1)‐dependent cell death in human colon cancer cells
. International Journal of Cancer 123:8, pages 1797-1806.
Crossref
Crossref
Jean-François RossignolEmmet B Keeffe. (2008) Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiology 3:5, pages 539-545.
Crossref
Crossref
Daniel M. Musher & Saima Aslam. 2008. Emerging Infections 8. Emerging Infections 8
313
335
.
Joachim Müller, Serej Ley, Ingrid Felger, Andrew Hemphill & Norbert Müller. (2008) Identification of differentially expressed genes in a Giardia lamblia WB C6 clone resistant to nitazoxanide and metronidazole. Journal of Antimicrobial Chemotherapy 62:1, pages 72-82.
Crossref
Crossref
Daniel M. Musher & Saima Aslam. (2008) Treatment of Clostridium Difficile Colitis in the Critical Care Setting. Critical Care Clinics 24:2, pages 279-291.
Crossref
Crossref
Olinda M. Delgado, Glory Fernandez, Sylvia Silva, Oriana Ramirez, Jesus Romero & Alfonso J. Rodriguez-Morales. (2008) Preliminary evidence of nitazoxanide activity on Toxocara canis in a mouse model. International Journal of Antimicrobial Agents 31:2, pages 182-184.
Crossref
Crossref
Patrice Bourée, Aurélia Lançon & Paula Resende. (2008) Parasitoses intestinales émergentes. Revue Francophone des Laboratoires 2008:399, pages 23-28.
Crossref
Crossref
Marcelo Donadel Malesuik, Simone Gonçalves Cardoso & Martin Steppe. (2007) Development of a Validated Stability-Indicating LC Method for Nitazoxanide in Pharmaceutical Formulations. Chromatographia 67:1-2, pages 131-136.
Crossref
Crossref
Joachim Müller, Arunasalam Naguleswaran, Norbert Müller & Andrew Hemphill. (2008) Neospora caninum: Functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Experimental Parasitology 118:1, pages 80-88.
Crossref
Crossref
Xicheng Sun, Joseph Guiles & Nebojsa Janjic. 2008.
269
279
.
Joachim Müller, Maaike Sterk, Andrew Hemphill & Norbert Müller. (2007) Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole. Journal of Antimicrobial Chemotherapy 60:2, pages 280-287.
Crossref
Crossref
Joachim Müller, Jonathan Wastling, Sanya Sanderson, Norbert Müller & Andrew Hemphill. (2007)
A Novel
Giardia lamblia
Nitroreductase, GlNR1, Interacts with Nitazoxanide and Other Thiazolides
. Antimicrobial Agents and Chemotherapy 51:6, pages 1979-1986.
Crossref
Crossref
Daniel M. Musher, Nancy Logan, Vaibhav Mehendiratta, Nicolas A. Melgarejo, Sagar Garud & Richard J. Hamill. (2007) Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. Journal of Antimicrobial Chemotherapy 59:4, pages 705-710.
Crossref
Crossref
R.G.K. Donald. 2007. Toxoplasma Gondii. Toxoplasma Gondii
505
539
.
D. M. Musher, N. Logan, R. J. Hamill, H. L. DuPont, A. Lentnek, A. Gupta & J.-F. Rossignol. (2006) Nitazoxanide for the Treatment of Clostridium difficile Colitis. Clinical Infectious Diseases 43:4, pages 421-427.
Crossref
Crossref
David B. Huang & A. Clinton White. (2006) An Updated Review on Cryptosporidium and Giardia. Gastroenterology Clinics of North America 35:2, pages 291-314.
Crossref
Crossref
David A. Bobak. (2006) Use of nitazoxanide for gastrointestinal tract infections: Treatment of protozoan parasitic infection and beyond. Current Infectious Disease Reports 8:2, pages 91-95.
Crossref
Crossref
Joachim Müller, Géraldine Rühle, Norbert Müller, Jean-François Rossignol & Andrew Hemphill. (2006)
In Vitro Effects of Thiazolides on
Giardia lamblia
WB Clone C6 Cultured Axenically and in Coculture with Caco2 Cells
. Antimicrobial Agents and Chemotherapy 50:1, pages 162-170.
Crossref
Crossref
A. Bonnin, F. Dalle, S. Valot, G. Dautin & M. Di Palma. (2006) Infections à cryptosporidies et à Cyclospora. EMC - Maladies infectieuses 3:1, pages 1-11.
Crossref
Crossref
Penny Lewthwaite, Geoffrey V Gill, C Anthony Hart & Nicholas J Beeching. (2005) Gastrointestinal parasites in the immunocompromised. Current Opinion in Infectious Diseases 18:5, pages 427-435.
Crossref
Crossref
Marco Esposito, Rebecca Stettler, Shelley L. Moores, Chandrakala Pidathala, Norbert Müller, Andrew Stachulski, Neil G. Berry, Jean-Francois Rossignol & Andrew Hemphill. (2005)
In Vitro Efficacies of Nitazoxanide and Other Thiazolides against
Neospora caninum
Tachyzoites Reveal Antiparasitic Activity Independent of the Nitro Group
. Antimicrobial Agents and Chemotherapy 49:9, pages 3715-3723.
Crossref
Crossref
Theresa J. Ochoa & A Clinton White. (2005) Nitazoxanide for Treatment of Intestinal Parasites in Children. Pediatric Infectious Disease Journal 24:7, pages 641-642.
Crossref
Crossref